By Josh Beckerman
Vanda Pharmaceuticals rejected a second acquisition proposal from Cycle Group Holdings, saying terms are economically identical to a previously rejected indication of interest and that it substantially undervalues Vanda.
"The board concluded that the latest proposal from Cycle Group is another opportunistic attempt to purchase the company's shares at a discount to Vanda's intrinsic value," Vanda said.
Vanda shares were higher after Cycle reaffirmed its $8-a-share proposal. The stock was recently up 11% to $4.94. Cycle alleges that actions such as Vanda's bylaw changes have disenfranchised stockholders.
In June, Vanda rejected proposals from Cycle and Future Pak.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 14, 2024 12:54 ET (16:54 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。